Zenith
Epigenetics

Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.

Learn More

About Zenith Epigenetics

Zenith Epigenetics Ltd. ("Zenith Epigenetics") is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.

Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer.

Our strong management team and organization allow us to efficiently and rapidly explore and progress molecules from discovery to clinical development. Our research team, based in Calgary, Alberta, is well-positioned to take advantage of its broad and longstanding experience in epigenetics to become a leader in the discovery of selective BET inhibitors in both oncology and other indications. The development activities are led by our San Francisco based team, where a strong emphasis on translational medicine to drive patient pre-selection combined with a proven track record in drug development, will allow us to excel in the field of epigenetics.

Zenith Epigenetics is a wholly-owned subsidiary of Zenith Capital Corp.

Events
Dec
12

Zenith Annual General Meeting of Shareholders

Tuesday, December 12, 2017 2:45pm MT

Mount Royal University
The Roderick Mah Centre for Continuous Learning
Ross Glen Hall, EC1040
4825 Mount Royal Gate SW
Calgary, Alberta

Webcast Link

Add This to my Calendar
Nov
07

BIO Europe 2017

November 6-8, 2017, Berlin, Germany

Presentation Date: Tuesday, November 7
Presentation Time: 3:15pm Local
Presentation will be available HERE at the time of live event

Read More Add This to my Calendar